NKTR NEKTAR THERAPEUTICS
Pharmaceutical Preparations · Nasdaq · SEC CIK 906709 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-16.6%
TTM net income YoY-46.8%
TTM EPS YoY18.0%
Revenue 3-yr CAGR-16.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-319.8%
Net margin-339.7%
FCF margin-493.4%
EBITDA margin-318.5%
Returns
ROE-37.9%
ROA-26.5%
ROIC (approx.)-30.7%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets18.1%
Debt / equity0.00x
Current ratio9.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.45x
Accruals ratio11.9%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $55.23M | $98.43M |
| Cost of revenue | $0 | $30.69M |
| Gross profit | $55.23M | $67.74M |
| R&D expense | $117.33M | $120.91M |
| SG&A expense | $68.67M | $76.75M |
| Operating income | -$140.10M | -$105.20M |
| Pretax income | -$164.21M | -$119.20M |
| Income tax | -$138,000 | -$239,000 |
| Net income | -$164.08M | -$118.96M |
| EBITDA | -$139.08M | -$100.81M |
| EPS (basic) | -9.73 | -8.68 |
| EPS (diluted) | -9.73 | -8.68 |
| Weighted avg. shares (diluted) | 16.87M | 13.71M |
| Balance sheet | ||
| Cash & equivalents | $15.12M | $44.25M |
| Short-term investments | $230.64M | $210.97M |
| Receivables | — | $0 |
| Inventory | $0 | $0 |
| Current assets | $266.27M | $261.29M |
| PP&E, net | $2.06M | $3.41M |
| Total assets | $280.41M | $303.85M |
| Current liabilities | $53.54M | $61.40M |
| Total liabilities | $190.57M | $243.11M |
| Shareholders' equity | $89.83M | $60.74M |
| Shares outstanding | 20.38M | 12.39M |
| Cash flow statement | ||
| Operating cash flow | -$208.51M | -$175.71M |
| Capital expenditure | $171,000 | $1.47M |
| Free cash flow | -$208.68M | -$177.18M |
| Investing cash flow | -$1.20M | $142.57M |
| Financing cash flow | $180.57M | $42.12M |
| Depreciation & amortization | $1.03M | $4.39M |
| Stock-based compensation | $12.65M | $21.61M |
| Share buybacks | $0 | $3.00M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.